ALVIMOPAN Drug Patent Profile
✉ Email this page to a colleague
When do Alvimopan patents expire, and when can generic versions of Alvimopan launch?
Alvimopan is a drug marketed by Hikma, Par Pharm, and Watson Labs Teva. and is included in three NDAs.
The generic ingredient in ALVIMOPAN is alvimopan. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alvimopan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alvimopan
A generic version of ALVIMOPAN was approved as alvimopan by WATSON LABS TEVA on December 19th, 2019.
Summary for ALVIMOPAN
Recent Clinical Trials for ALVIMOPAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oregon Health and Science University | Phase 4 |
| CMC Ambroise Paré | Phase 3 |
| Scott Steele | Phase 4 |
Pharmacology for ALVIMOPAN
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ALVIMOPAN
US Patents and Regulatory Information for ALVIMOPAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | ALVIMOPAN | alvimopan | CAPSULE;ORAL | 217753-001 | Aug 31, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Par Pharm | ALVIMOPAN | alvimopan | CAPSULE;ORAL | 216843-001 | Jan 24, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Watson Labs Teva | ALVIMOPAN | alvimopan | CAPSULE;ORAL | 208295-001 | Dec 19, 2019 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
